Trial Profile
A Real World Study Comparing Effectiveness, Treatment Patterns, and Costs in Type 2 Diabetes Mellitus (T2DM) Patients Initiated on Canagliflozin or a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jul 2018
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Glucagon like peptide 1 receptor agonists (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 20 Jul 2018 New trial record
- 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association.